Option chain shows key data for Biotricity's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Biotricity.

Biotricity (OTC:BTCY) Stock, Option Chain

Biotricity

Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LGVN

LOCL

MNDR

MRNS

NMRA

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

ONVO

PROK

PSNY

QTTB

RARE

RENT

SNGX

SNPO

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

AGRI

ANTE

BFRI

BTTX

CISO

CURO

EVLV

GXAI

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INMD

IOVA

LICN

LUNR

LXRX

MEDS

MNPR

OCGN

OPEN

QBTS

QRTEA

RAPT

SIEN

SISI

SMCI

SMMT

SPRC

SSRM

TANH

TIRX

TNYA

TVGN

VZIO

Shares of  Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.

Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

ACMR

AIRE

AMZN

APLM

APPF

ARCB

BHAT

BHIL

BKYI

BREA

BWMX

CUBI

DECK

DXCM

ENPH

EXPO

GNLX

GTLS

IBRX

IMTE

INTC

KNSL

LRHC

MDNA

NKGN

NRDS

NVVE

RNAZ

RVSN

SAIA

SECO

SYTA

TMPO

VVOS

Gainers


	Apollomics, Inc.  (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion.


Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Biotricity Inc

WIIM

SMTK

SmartKem shares are trading higher after the company announced it received a £900,000 grant from Innovate UK and commenced a $7.65 million offering of common stock and class D warrants.

JPMorgan analyst Doug Anmuth has rolled out an optimistic<a href="https://www.benzinga.com/markets/24/12/42497093/stock-market-predictions-for-2025-a-mixed-bag-of-expectations"> internet 2025 outlook</a>, emphasizing mega-cap tech leaders as top picks. The big winners? Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google, and Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>). 
Despite "heavy capex investments," Anmuth expects "increasing returns" as artificial intelligence shifts to practical applications, driving growth in advertising, cloud, and software tools.
<h2 class="wp-block-heading">Why 2025 Looks Promising</h2>
Anmuth highlights three transformative AI trends reshaping the tech landscape:
<ol>
<li>A 30% boost in engineering efficiency across major companies.</li>
<li>Billions in AI revenue for AWS and Google Cloud.</li>
<li>Accelerated ad and search growth for Meta and Google, driven by improved targeting and conversions.</li>
</ol>
These advancements, coupled with a pro-business political backdrop and stabilized macro trends, are set to support strong revenue growth across the Internet sector in 2025.
Read Also: <a href="https://www.benzinga.com/24/12/42556006/amazon-to-rally-around-21-here-are-10-top-analyst-forecasts-for-wednesday">Amazon To Rally Around 21%?</a>
<h2 class="wp-block-heading">Capex Surge: A Long-Term Play</h2>
Big tech is gearing up for significant infrastructure spending in 2025, exceeding market expectations. 
Anmuth projects capex of $97 billion for Amazon, $64 billion for Meta, and $62 billion for Alphabet. While these investments may weigh on margins, the long-term outlook remains bullish. 
Amazon and Alphabet are forecasted to expand margins and free cash flow, while Meta's outlook is steadier, despite double-digit revenue and EPS growth expectations.
<h2 class="wp-block-heading">Stock-Specific Highlights</h2>
<ul>
<li>Amazon (Target Price: $280) Amazon&#8217;s dominance in e-commerce and cloud markets positions it for multi-year margin and free cash flow expansion. With high-growth AWS and advertising streams, the company is poised to capitalize on untapped potential in IT and retail digitization.</li>
<li>Alphabet (Target Price: $232) Alphabet's ad business and AI-driven innovation keep it ahead of the pack. Search, YouTube ads, and cloud services present robust growth opportunities, while its "Other Bets" businesses like Waymo and Verily add optionality.</li>
<li>Meta Platforms (Target Price: $725) Meta's dual focus on AI and the metaverse underscores its commitment to long-term growth. Despite increased infrastructure spending, Meta's unmatched reach and targeting capabilities ensure sustained profitability and value for advertisers.</li>
<li>Spotify (Target Price: $555) Spotify continues to ride the audio streaming wave with solid user growth, cost discipline, and profit gains from podcasts and marketplace contributions.</li>
</ul>
As AI matures, these mega-cap tech leaders are well-positioned to reap the rewards of their massive investments. 
While elevated capex may challenge short-term margins, the broader narrative of innovation, efficiency, and market dominance paints a bullish picture for 2025. 
For investors, JPMorgan's favorites—Amazon, Meta, Alphabet, and Spotify—stand as compelling opportunities to capitalize on the next phase of tech evolution.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42548075/us-stock-markets-outsized-influence-resurges-as-it-dominates-two-thirds-of-msci-world-indexs-capitalization-mirroring-late-1980s-peak">US Stocks Led By Apple, Nvidia, And Other Tech Giants Dominate Nearly Two-Thirds Of MSCI World Index, Drawing Parallels To 1980s Peak</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Long Ideas

Analyst Ratings

Tech

GOOG

GOOGL

SPOT

Amazon, Meta, Alphabet, Spotify Lead JPMorgan's 2025 Tech Picks For AI Potential

Meta Platforms Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Instagram has the potential to generate 50% of the company&#8217;s advertising revenue in the U.S., Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-12-18/instagram-expected-to-generate-50-of-meta-s-us-ad-sales-in-2025?sref=TBDibEcD" rel="noreferrer noopener">cites</a> from Emarketer estimates.
Instagram could breach $32 billion in U.S. advertising revenue in 2025, up over 24% in 2024, as its short-form video product Reels gain traction, Bloomberg cites Emarketer. The video-sharing app boasts over 148 million American users.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42554393/disneys-marvel-rivals-game-hits-20-million-players-proves-superhero-power-still-reigns" rel="noreferrer noopener">Disney&#8217;s Marvel Rivals Game Hits 20 Million Players, Proves Superhero Power Still Reigns</a>
By early 2022, Instagram accounted for nearly 30%&nbsp;of Meta&#8217;s global business from 27% in 2021, Bloomberg cited court filings.
Reels competes with ByteDance&#8217;s TikTok and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) YouTube Shorts.
Meta&#8217;s focus on video content has been instrumental to its growth, as users devoted nearly 67% of their Instagram time to surfing videos, Bloomberg cited Jasmine Enberg of Emarketer.
<a target="_blank" href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling" rel="noreferrer noopener">The TikTok ban</a> could serve as a tailwind for Instagram, helping it win over 20% of reallocated TikTok ad dollars in the U.S, Reuters cites Enberg.
Meta previously told Instagram Reels accounted for over 50%&nbsp;of the time people spend on the app.
In 2024, 53.7% of Instagram&#8217;s ad revenue primarily came from its Feed features and 24.6% from Stories features. With Reels&#8217; revenue boost, the combined revenue share from Instagram Explore, Reels, and Threads could rise 9.6% in 2025.
In October, BofA Securities analyst Justin Post <a target="_blank" href="https://www.benzinga.com/news/24/10/41465662/metas-reels-monetization-and-ai-innovations-drive-top-ai-pick-analyst" rel="noreferrer noopener">projected Meta&#8217;s upside</a> from ramping up Messaging and Reel monetization powered by new artificial intelligence tools and CRM integration.
Meta Platforms stock surged 79% year-to-date. Investors can gain exposure to the stock through Vanguard Communication Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>) and The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>).
<h2 class="wp-block-heading">Is Meta A Good Stock To Buy?</h2>
An investor or trader's decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision. 
For example, for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), you'll notice that earnings in its last quarter grew 14.86% <a href="https://www.benzinga.com/quote/META/earnings">source</a>. As an investor, you'll want to decide whether that's better or worse than what you'd like to see among stocks in your portfolio. 
On the valuation side, Meta Platforms's price to earnings ratio &#8211; a measure of how much an investor pays for the company's earnings &#8211; is compressed 15.56% in the current quarter when compared with last year. That places it below similar businesses Alphabet, Baidu, Pinterest in its sector. You'll need to decide whether that makes it more or less attractive based on how you think the company will perform over time.
There are many different valuation metrics that may help you make a decision. Find more on <a href="https://www.benzinga.com/quote/META">Meta Platforms's quote page</a>, or if you'd like a deeper dive in an advanced program, try <a href="https://pro.benzinga.com">Benzinga PRO</a> for free.
Price Action: META stock is up 1.15% at $626.545 at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42553094/jabil-q1-earnings-tops-expectations-cloud-and-data-center-growth-outlook" target="_blank" rel="noreferrer noopener">Jabil Q1 Earnings: Revenue And EPS Beat, Cloud and Data Center Growth, Raises Annual Outlook</a></li>
</ul>
Photo via Shutterstock

Media

Instagram's Ad Revenue Could Hit $32 Billion by 2025, Driving Meta's Growth: Report

AZTA

Azenta shares are trading higher after Stephens & Co. upgraded the stock to Overweight from Equal-Weight and raised its price target from $50 to $60.

Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) stock is trading higher on Wednesday after the company announced it secured a 400 MWh <a href="https://www.benzinga.com//node/42552632">standalone storage order</a> with International Electric Power.
The Details: This order is part of a project to be deployed at Marine Corps Base Camp Pendleton in San Diego, California which aims to enhance grid resiliency for the U.S. Navy and Marine Corps.
The project, supported by funding from the California Energy Commission's Long Duration Energy Storage Program, will use Eos Z3 batteries and is scheduled for delivery beginning in 2025. The Eos Z3 Cubes are safe, non-flammable and don't require cooling systems, which helps minimize noise and reduce operational costs.
&#8220;IEP and CEC are at the forefront of North American long-duration energy storage, and their partnership has been invaluable as Eos transitions into a profitable operating company. They recognize the need for multiple storage technologies and the energy security that an American-made product provides,&#8221; added Joe Mastrangelo, Eos CEO.
&#8220;It&#8217;s an honor to have been selected for such an important installation at Camp Pendleton.&#8221;
Related Link: <a href="https://www.benzinga.com/insights/options/24/12/42557838/palantir-technologies-unusual-options-activity">Palantir Technologies Unusual Options Activity</a>
EOSE Price Action: At the time of writing Eos Energy stock is trading 14.7% higher at $4.48, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Shutterstock

EOSE

What's Going On With Eos Energy Stock Wednesday?

Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TH#TSX">TH</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has submitted a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) describing the changes made to the manufacturing environment of the facility where EGRIFTA SV&#xAE; is produced. A PAS is reviewed by the FDA within four months of receipt and an approval is needed prior to the distribution of the <a href="https://www.globenewswire.com/Tracker?data=8zHQ9qiyFO30h9BOfieWluYkNSdMsyvq24uHfuCufIVJuAcz2MC2Wi8JwO3uxPJK5Zg4Hnxe9yRK0YL8b-VwzIBT6sI1dIqefPxyrQH9SQcGs96Be7BtzwxdO12cw4ciN0DBUaDXb2Ey9HpTsYJ1aBwYpdHX5l1dgbBweAE30nUjyjJdJMuySCqOg_9-Q9R4FdrlVrl3X8KTmjgYmunrjBVx1NwAWJWd66efKQ6DFRo=">recently manufactured</a> batches of&nbsp;EGRIFTA SV&#xAE;.
Existing inventory levels of&nbsp;EGRIFTA SV&#xAE; are expected to meet patient demand until mid-January 2025. Theratechnologies therefore continues discussions with the relevant FDA divisions in an effort to accelerate the release of EGRIFTA SV&#xAE; and avoid a product shortage at the patient level.
The Company will update the market on any further material developments.
EGRIFTA SV&#xAE; is distributed in the United States only.

Biotech

General

THTX

TSX:TH

Theratechnologies Has Submitted A Prior Approval Supplement To The U.S. FDA Describing The Changes Made To The Manufacturing Environment Of The Facility Where EGRIFTA SV Is Produced

D-Wave Quantum shares are trading higher amid continued volatility in quantum stocks.

<a href="https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr" title="https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr">https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr</a>

Contracts

PYPL

Reported Earlier, 'Bureau Secures $30M From Sorenson Capital, PayPal Ventures, Existing Investors' - Economic Times

In the current session, the stock is trading at $93.06, after a 0.44% spike. Over the past month, Lantheus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock increased by 7.65%, and in the past year, by 56.81%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_0.png" alt="Past Year Chart" />

<h3>Lantheus Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lantheus Holdings has a lower P/E than the aggregate P/E of 48.6 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

LNTH

P/E Ratio Insights for Lantheus Holdings

NUKK

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 377%

Nukkleus Inc Shares Resume Trading

EGHT

8x8 shares are trading higher after Morgan Stanley raised its price target on the stock from $2 to $2.6.

Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) heads into its <a href="https://www.benzinga.com/quote/MU/earnings">first-quarter earnings</a> announcement with a mix of optimism and caution.
<h1 class="wp-block-heading">"Choppy Quarters Ahead"?</h1>
As Jake Silverman, Bloomberg Intelligence Semiconductor Analyst, puts it, "choppy quarters ahead for NAND" could pose a challenge, with pricing and inventory pressures in the smartphone and PC markets.
However, the analyst also highlights AI-related applications as a potential offset, giving Micron a chance to weather the storm.
Read Also: <a href="https://www.benzinga.com/24/12/42553082/how-to-earn-500-a-month-from-micron-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Micron Stock Ahead Of Q1 Earnings</a>
<h1 class="wp-block-heading">Bullish Technical Signals Keep Optimists In The Game</h1>
Micron's stock, currently trading at $110.93, flashes bullish signs across key technical indicators. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM.png" alt="" class="wp-image-698134" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
It sits well above short- and medium-term moving averages, with the eight-day simple moving average (SMA) at $103.94, the 20-day SMA at $102.07 and the 50-day SMA at $104.07. 
The Moving Average Convergence Divergence (MACD) at 1.15 also suggests momentum is on the bulls' side.
However, the 200-day SMA of $110.93 coincides with the price, remaining a hurdle, signaling a potential resistance level.
<h1 class="wp-block-heading">AI: A Light At The End Of The NAND Tunnel?</h1>
The market will be laser-focused on how Micron balances the dynamics of two divergent forces:
<ol>
<li>NAND Weakness: Elevated inventories and pricing pressure.</li>
<li>AI Opportunities: As Silverman notes, secular growth in AI applications could provide a much-needed boost, potentially offsetting the broader NAND market challenges.</li>
</ol>
<h1 class="wp-block-heading">What's Expected?</h1>
Analysts estimate an EPS of $1.76 and revenue of $8.72 billion. But beyond these numbers, investors will be scrutinizing the company's guidance. Can Micron sustain its AI-driven growth momentum, or will "choppy quarters" in NAND drag it down?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/12/42549182/us-stocks-to-open-higher-as-rate-cut-expectations-surge-all-eyes-on-dow-jones-to-break-its-9-day-losing-streak">US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak</a></li>
</ul>
Photo: NPS_87 on Shutterstock

Technicals

Previews

Micron Earnings: Will AI Growth Outweigh 'Choppy' Memory Market?

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 319.6%

With Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices peaking to all-time high levels, MicroStrategy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) aggressive Bitcoin accumulation strategy has once again become a focal point in discussions among <a href="https://www.benzinga.com/markets/equities/24/12/42503221/microstrategy-shares-surge-nearly-7-amid-nasdaq-100-inclusion-and-bitcoins-new-record-high">traders and analysts</a>.
What Happened: In a tweet on Monday, industry expert Alex Kolicich addressed common misconceptions about MSTR in a recent tweet, explaining that the stock is neither a leveraged nor a synthetic call option on Bitcoin. 
Instead, Kolicich pointed out several structural inefficiencies:
<ul>
<li>MSTR trades at a 140% premium to its Bitcoin holdings&#8217; net asset value (NAV).</li>
<li>Each $1 invested in MSTR stock provides only $0.45 of Bitcoin exposure, far less than direct Bitcoin ownership.</li>
</ul>
Kolicich further <a href="https://x.com/AlexKolicich/status/1868705490387321177">elaborated</a> that MicroStrategy is not leveraged but instead deleveraged, offering reduced Bitcoin exposure compared to direct investments. 
He highlighted alternatives like BITX, which provide 2x leverage without a NAV premium.
Additionally, while traditional call options on assets typically offer leveraged upside due to their long volatility exposure, MSTR's convertible bonds effectively short volatility, diluting shareholder returns as Bitcoin prices rise.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42509614/microstrategy-expands-bitcoin-holdings-by-15350-btc-worth-15-billion-after-joining-nasdaq-100">MicroStrategy Expands Bitcoin Holdings By 15,350 BTC Worth $1.5 Billion After Joining Nasdaq 100</a>
Why It Matters: Crypto trader TheFlowHorse on Dec. 17 in a post on X emphasized the implications of Saylor&#8217;s aggressive Bitcoin purchases, noting that these acquisitions have significantly raised MicroStrategy's DCA to $61,000. 
This figure is approximately 40% higher than Bitcoin's current price, introducing potential risks if prices fail to recover significantly.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Take a look at Saylor&#39;s recent Bitcoin buys. The buys up here are so large that he has increased his dollar cost average price by nearly 50%, to 61k. That level is around 40% away. We haven&#39;t had a pullback of that magnitude for years, but at some point you have to wonder if in… <a href="https://t.co/erhdvrErn2">pic.twitter.com/erhdvrErn2</a>
&mdash; HORSE (@TheFlowHorse) <a href="https://twitter.com/TheFlowHorse/status/1868763016642052542?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Analysts warn that while Bitcoin&#8217;s pullbacks have historically been rare, Saylor's strategy could leave MSTR exposed to potential downside risk, especially with its C-Corp structure subject to double taxation, unlike <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42275232/leveraged-microstrategy-etfs-are-playing-with-fire-experts-warn">more efficient ETFs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42522606/trump-is-serious-about-creating-a-bitcoin-reserve-says-microstrategys-michael-saylorurges-to-buy-btc-before-it-goes-up-by-100x">Trump Serious About Bitcoin Reserve, Says MicroStrategy&#8217;s Michael Saylor: &#8216;Buy It Now And Own The Future&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy's Aggressive Bitcoin Strategy Raises Eyebrows In Crypto Community

Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42550503/corvus-pharmaceuticals-announces-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-so" rel="noreferrer noopener">severe atopic dermatitis</a>.&nbsp;
The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy.
These doses were selected based on the company&#8217;s prior experience evaluating soquelitinib in T-cell lymphoma patients.
The company is reporting complete results from Cohort 1 of the trial, which includes 16 patients (12 who received soquelitinib 100 mg oral twice per day and four who received placebo), with follow-up at 28 days and 58 days.
The mean baseline EASI and IGA scores for soquelitinib patients were 20.4 and 3.0, respectively, compared to 18.5 and 3.3 for placebo patients.
EASI scores at 28-day and 58-day follow-up demonstrate a favorable effect of soquelitinib treatment compared to placebo.
The soquelitinib mean EASI score reduction was 55.9% at 28 days (n=12) compared to mean EASI reduction of 27.0% in placebo. At day 58, continued improvement in the soquelitinib group was seen with mean EASI reduction of 69.1% (n=10) compared to mean EASI reduction of 19.1% for the placebo group.
<ul>
<li>At day 28, in the soquelitinib group, nine of 12 patients achieved EASI 50; three of 12 achieved EASI 75 and one of 12 achieved EASI 90. Three of the 12 patients achieved IGA 0 or 1. In the placebo group, two of four patients achieved EASI 50 and none achieved EASI 75, EASI 90, or IGA 0 or 1.</li>
<li>At day 58, in the soquelitinib group, nine of 10 patients achieved EASI 50, four of 10 achieved EASI 75 and one of 10 achieved EASI 90. Three of 10 patients achieved IGA 0 or 1. In the placebo group, one in four patients achieved EASI 50, and no patients achieved EASI 75, EASI 90, or IGA 0 or 1.</li>
</ul>
No significant safety issues were observed. All the patients completed 28 days of dosing. One patient reported Grade 1 nausea that did not interfere with the subject receiving the full treatment course, and one patient developed COVID-19 on day 28 of treatment; that patient had an uneventful recovery.
Price Action: CRVS stock is down 36.80% at $4.67 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/12/42556198/united-microelectronics-signs-landmark-renewable-energy-deal-with-fengmiao-i-offshore-wind-farm-stock-gains" target="_blank" rel="noreferrer noopener">United Microelectronics Signs Landmark Renewable Energy Deal with Fengmiao I Offshore Wind Farm, Stock Gains</a></li>
</ul>

Health Care

CRVS

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Toyota Motor shares are trading higher. The company announced it received funding from the US Department of Energy for the development of EV battery life cycles.

NVDA

NVIDIA shares are trading higher amid overall market strength ahead of the Fed's decision. Additionally, Omdia estimated that Microsoft bought 485,000 of Nvidia's Hopper chips this year.

PLTR

Palantir Technologies shares are trading higher after the company joined forces with Pray.com to enhance multilingual faith-based content using advanced AI technology.

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) shares are trading lower Wednesday, pulling back from a recent surge that saw the stock join the $1 trillion club. Here&#8217;s a look at what <a href="https://www.benzinga.com/24/12/42536512/market-breadth-worsens-as-tech-giants-break-free-from-sp-500-reality-is-this-bullish-or-bearish-for-2025">you need to know</a>.
What To Know: Broadcom shares have been on a tear over the past week, gaining nearly 40% since <a href="https://www.benzinga.com/news/earnings/24/12/42472970/broadcom-reports-mixed-q4-results-eps-beat-revenues-miss-q1-guidance-in-line-with-estimates">reporting earnings</a>. Broadcom shares soared after the company beat earnings estimates and provided strong guidance for AI-related revenue growth.
Broadcom&#8217;s fourth-quarter revenue was up 51% year-over-year to $14.05 billion, but came up short of estimates of $14.09 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Despite the miss on overall revenue, Broadcom reported a 220% increase in AI revenue and guided for significant growth in 2025. Positive commentary surrounding AI on the call also helped drive momentum to the upside.
Broadcom CEO Hock Tan said on the call with analysts and investors that he expects the total addressable market for the company&#8217;s AI chips to be between $60 billion and $90 billion over the next few years. He also announced that the company was working on custom AI chips with large cloud customers, <a href="https://www.cnbc.com/2024/12/13/broadcom-stock-jumps-21percent-pushing-company-past-1-trillion-market-cap-for-the-first-time.html">per</a> CNBC.
Reports from last week suggested that Broadcom was working with Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) on <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42439155/broadcom-stock-jumps-on-apple-ai-chip-report-whats-going-on">AI chip development</a>. The company is reportedly working on development of an AI server chip&#8217;s networking technology. Broadcom shares got a boost from the news. 
Several analysts have weighed in with positive updates since the company reported fourth-quarter results. Multiple analysts maintained Overweight ratings, while others kept Buy ratings on the name. Newly-issued price targets range from $205 to $255. 
The weakness in Broadcom shares on Wednesday appears to be due to profit-taking in the wake of Broadcom&#8217;s incredible surge above the $1 trillion market cap mark. Broadcom shares hit new all-time highs this week, so the stock is likely to remain volatile as investors try to determine the appropriate value of the stock given the recent string of AI news.
It&#8217;s worth noting that Broadcom was among the top trending stocks on Reddit&#8217;s WallStreetBets on Wednesday, suggesting retail investors are also sizing up the name.
Check This Out: <a href="https://www.benzinga.com/24/12/42531167/broadcom-dethrones-nvidia-as-ais-new-darling-valuation-multiple-suggests-ai-momentum-shift">Broadcom Outpaces Nvidia In AI Chip Stock Valuation Race: Is Investor Sentiment Shifting?</a>
AVGO Price Action: <a href="http://benzinga.com/quote/avgo">Broadcom shares</a> were down 3.33% at $232.18 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

AAPL

AVGO

What's Going On With Broadcom Stock?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biotricity (NASDAQ:<a href="https://investorplace.com/stock-quotes/btcy-stock-quote/">BTCY</a>) just reported results for the first quarter of 2025.<ul><li>Biotricity reported earnings per share of -7.5 cents.</li><li>The company reported revenue of $3.20 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/btcy-stock-earnings-biotricity-for-q1-of-2025/">BTCY Stock Earnings: Biotricity Reported Results for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BTCY Stock Earnings: Biotricity Reported Results for Q1 2025

Biotricity reports Q1 results

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biotricity (NASDAQ:<a href="https://investorplace.com/stock-quotes/btcy-stock-quote/">BTCY</a>) just reported results for the first quarter of 2025.<ul><li>Biotricity reported earnings per share of -7.5 cents.</li><li>The company reported revenue of $3.20 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/btcy-stock-earnings-biotricity-for-q1-of-2025/">BTCY Stock Earnings: Biotricity Reported Results for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Biotricity reaches EBITDA positive on go-forward cash basis

Reports Q2 revenue $3.3M vs. $2.89M last year. Waqaas Al-Siddiq, CEO, said, "In the second quarter of fiscal 2025, we continued our mission to prod...

Biotricity reports Q2 EPS (7c) vs. (44c) last year

Biotricity GAAP EPS of -$0.07, revenue of $3.3M

Biotricity, Inc. (BTCY) Q2 2025 Earnings Call Transcript

Biotricity ( ($BTCY) ) has released its Q2 earnings. Here is a breakdown of the information Biotricity presented to its investors. Biotricity Inc. ...

Biotricity Reports Revenue Growth Amidst Ongoing Losses

Comments

Biotricity

Biotricity (BTCY) Options

Loading...

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga